Skip to content

Intermountain Stewardship in Community Outpatient Settings-Resources & Engagement-Pediatrics

Intermountain Stewardship in Community Outpatient Settings-Resources & Engagement-Pediatrics

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07334795
Acronym
SCORE-Peds
Enrollment
259000
Registered
2026-01-12
Start date
2026-01-15
Completion date
2029-01-15
Last updated
2026-03-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Antibiotic, Antibiotic Duration, Antibiotic Prescribing for Acute Respiratory-tract Infections, Respiratory Infection (for Example, Pneumonia, Bronchitis)

Brief summary

The goal of this implementation project is to detail the process of implementing the best practice of antibiotic stewardship in the pediatric population across the Intermountain Health medical system. The main questions it aims to answer are: * How can a large healthcare system drive high adherence to antibiotic stewardship across a large and diverse number of sites? * How do determinants of implementation and needed strategies vary by context? * What is the utility of a higher-resource implementation effort (named "Boost) focusing on outlier sites? Data will be collected on number of children reached, adherence changes over time, types of implementation strategies employed, and characteristics of sites, prescribers, and patients.

Interventions

OTHERImplementation strategies including training & education, EMR tools, audit & feedback reports, and facilitation

o facilitate improved adherence to guideline-based prescribing, we plan a variety of implementation strategies to be employed in tandem including training \& education, EMR tools (e.g., Smart sets, express lanes, preference lists), audit and feedback reports and dashboards, and facilitation.

Sponsors

Intermountain Health Care, Inc.
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
6 Months to 17 Years
Healthy volunteers
No

Inclusion criteria

* Age 6 months through 17 years * ARTI diagnosis (acute otitis media (AOM), Group A Streptococcal (GAS) pharyngitis, acute sinusitis, and community-acquired pneumonia (CAP))

Exclusion criteria

* Age \<6months or \>18 years * No ARTI diagnosis

Design outcomes

Primary

MeasureTime frameDescription
Guideline-adherent Broad vs. Narrow Spectrum Antibiotic PrescribingBaseline month adherence and post implementation (12 months). Maintenance period is 6 months post implementation.Rates of narrow-spectrum antibiotic (AB) prescriptions as a proportion of all antibiotics prescribed in aggregate and within each of these diagnoses: Acute otitis media, Group A streptococcal pharyngitis, Acute sinusitis, and Pneumonia.
Guideline-adherent Duration of Antimicrobial TherapyBaseline month adherence and post implementation (12 months). Maintenance period is 6 months post implementation.Rate of AB prescriptions with guideline-adherent number of days prescribed as proportion of all AB prescriptions in aggregate and for each of the target ARTI diagnoses.

Secondary

MeasureTime frameDescription
Rate of Treatment FailureBaseline month adherence and post implementation (12 months). Maintenance period is 6 months post implementationClinical encounter for the same diagnosis between 2 and 14 days following the index encounter and receipt of an alternative antibiotic for the same respiratory diagnosis during the return visit.
Adoption (Staff): Adherence to ProtocolsBaseline month adherence and post implementation (12 months). Maintenance period is 6 months post implementationNumber and proportion of prescribers who are "adherent" to guideline-based prescribing protocols for Broad vs. Narrow Spectrum AB Prescribing, and Duration.
Adoption (Organization): Adherence to ProtocolsBaseline month adherence and post implementation (12 months). Maintenance period is 6 months post implementation.Number and proportion of sites where 60% of prescribers are adherent.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 10, 2026